Apimeds Pharmaceuticals US (APUS) Total Debt (2025)

Apimeds Pharmaceuticals US (APUS) reported Total Debt of $1.6 million for Q4 2025, up 546.77% quarter-over-quarter from $250000.0 in Q1 2025.

Apimeds Pharmaceuticals US (APUS) Total Debt (2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Total Debt for 1 years, with the latest figure at $1.6 million in Q4 2025.

  • For the quarter ending Q4 2025, Total Debt changed N/A year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $1.6 million (changed N/A YoY), and the FY2025 full-year result was $1.6 million, changed N/A from the prior year.
  • Total Debt for Q4 2025 stood at $1.6 million, up from $250000.0 in the prior quarter.
  • The five-year high for Total Debt was $1.6 million in Q4 2025, with the low at $250000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 16.63 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 9.05 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 3.53 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 3.99 Bn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 1.51 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 570.41 Mn
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn - 1.62 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 1.62 Mn
Mar 31, 2025 250,000.00